Literature DB >> 21770894

MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines.

Xiqiang Liu1, Cheng Wang, Zujian Chen, Yi Jin, Yun Wang, Antonia Kolokythas, Yang Dai, Xiaofeng Zhou.   

Abstract

Down-regulation of miR-138 (microRNA-138) has been frequently observed in various cancers, including HNSCC (head and neck squamous cell carcinoma). Our previous studies suggest that down-regulation of miR-138 is associated with mesenchymal-like cell morphology and enhanced cell migration and invasion. In the present study, we demonstrated that these miR-138-induced changes were accompanied by marked reduction in E-cad (E-cadherin) expression and enhanced Vim (vimentin) expression, characteristics of EMT (epithelial-mesenchymal transition). On the basis of a combined experimental and bioinformatics analysis, we identified a number of miR-138 target genes that are associated with EMT, including VIM, ZEB2 (zinc finger E-box-binding homeobox 2) and EZH2 (enhancer of zeste homologue 2). Direct targeting of miR-138 to specific sequences located in the mRNAs of the VIM, ZEB2 and EZH2 genes was confirmed using luciferase reporter gene assays. Our functional analyses (knock-in and knock-down) demonstrated that miR-138 regulates the EMT via three distinct pathways: (i) direct targeting of VIM mRNA and controlling the expression of VIM at a post-transcriptional level, (ii) targeting the transcriptional repressors (ZEB2) which in turn regulating the transcription activity of the E-cad gene, and (iii) targeting the epigenetic regulator EZH2 which in turn modulates its gene silencing effects on the downstream genes including E-cad. These results, together with our previously observed miR-138 effects on cell migration and invasion through targeting RhoC (Rho-related GTP-binding protein C) and ROCK2 (Rho-associated, coiled-coil-containing protein kinase 2) concurrently, suggest that miR-138 is a multi-functional molecular regulator and plays major roles in EMT and in HNSCC progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770894      PMCID: PMC3331719          DOI: 10.1042/BJ20111006

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Differential growth factor regulation of N-cadherin expression and motility in normal and malignant oral epithelium.

Authors:  Michelle E Diamond; Limin Sun; Adam J Ottaviano; Mathew J Joseph; Hidayatullah G Munshi
Journal:  J Cell Sci       Date:  2008-06-10       Impact factor: 5.285

2.  Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue.

Authors:  Thian-Sze Wong; Xiao-Bing Liu; Birgitta Yee-Hang Wong; Raymond Wai-Man Ng; Anthony Po-Wing Yuen; William Ignace Wei
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

3.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

4.  Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines.

Authors:  Shingo Mitomo; Chihaya Maesawa; Satoshi Ogasawara; Takeshi Iwaya; Masahiko Shibazaki; Akiko Yashima-Abo; Koji Kotani; Hiroki Oikawa; Eiich Sakurai; Naoko Izutsu; Kuniyuki Kato; Hideaki Komatsu; Kenichro Ikeda; Go Wakabayashi; Tomoyuki Masuda
Journal:  Cancer Sci       Date:  2008-01-14       Impact factor: 6.716

5.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.

Authors:  Cameron P Bracken; Philip A Gregory; Natasha Kolesnikoff; Andrew G Bert; Jun Wang; M Frances Shannon; Gregory J Goodall
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

6.  Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor.

Authors:  Nicolás Herranz; Diego Pasini; Víctor M Díaz; Clara Francí; Arantxa Gutierrez; Natàlia Dave; Maria Escrivà; Inma Hernandez-Muñoz; Luciano Di Croce; Kristian Helin; Antonio García de Herreros; Sandra Peiró
Journal:  Mol Cell Biol       Date:  2008-06-02       Impact factor: 4.272

7.  Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling.

Authors:  Thian-Sze Wong; Xiao-Bing Liu; Ambrose Chung-Wai Ho; Anthony Po-Wing Yuen; Raymond Wai-Man Ng; William Ignace Wei
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.

Authors:  Philip A Gregory; Andrew G Bert; Emily L Paterson; Simon C Barry; Anna Tsykin; Gelareh Farshid; Mathew A Vadas; Yeesim Khew-Goodall; Gregory J Goodall
Journal:  Nat Cell Biol       Date:  2008-03-30       Impact factor: 28.824

9.  Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.

Authors:  Satoshi Fujii; Atsushi Ochiai
Journal:  Cancer Sci       Date:  2008-04       Impact factor: 6.716

10.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.

Authors:  Ulrike Burk; Jörg Schubert; Ulrich Wellner; Otto Schmalhofer; Elizabeth Vincan; Simone Spaderna; Thomas Brabletz
Journal:  EMBO Rep       Date:  2008-05-16       Impact factor: 8.807

View more
  94 in total

1.  A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer.

Authors:  Aldema Sas-Chen; Roi Avraham; Yosef Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-02-12       Impact factor: 2.673

2.  Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression.

Authors:  B O Sun; Yantian Fang; Zhenyang Li; Zongyou Chen; Jianbin Xiang
Journal:  Biomed Rep       Date:  2015-07-27

3.  MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours.

Authors:  Linli Tian; Minghua Li; Jingchun Ge; Yan Guo; Yanan Sun; Ming Liu; Hui Xiao
Journal:  Tumour Biol       Date:  2014-04-01

4.  Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.

Authors:  Lihong Han; Guoxiu Zhang; Nali Zhang; Haiyan Li; Yanyan Liu; Aiguo Fu; Youguang Zheng
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 5.  Microenvironmental regulation of cancer metastasis by miRNAs.

Authors:  Yun Zhang; Pengyuan Yang; Xiao-Fan Wang
Journal:  Trends Cell Biol       Date:  2013-10-11       Impact factor: 20.808

Review 6.  Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs.

Authors:  Samy Lamouille; Deepa Subramanyam; Robert Blelloch; Rik Derynck
Journal:  Curr Opin Cell Biol       Date:  2013-02-20       Impact factor: 8.382

Review 7.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

8.  Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma.

Authors:  Zujian Chen; Yi Jin; Dongsheng Yu; Anxun Wang; Ishrat Mahjabeen; Cheng Wang; Xiqiang Liu; Xiaofeng Zhou
Journal:  Oral Oncol       Date:  2012-03-17       Impact factor: 5.337

9.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

10.  Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Bin Xu; Da-Yong Jin; Wen-Hui Lou; Dan-Song Wang
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.